NEW YORK (GenomeWeb News) – Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF) and Adiga Life Sciences announced today a collaboration to identify proteomic and genomic biomarkers for monitoring the effectiveness of allergy vaccines.
Knowledge gained from the project is expected to lead to a better understanding of how such vaccines work, which will then be used to guide development of molecular tests for diagnosing and managing allergic rhinitis, PROOF said.
Adiga is currently collaborating with researchers from AllerGen NCE — a network of allergy and immune disease experts in Canada whose goal is to discover the causes of allergies and immune-related diseases — in a clinical trial with patients being treated with an investigational peptide allergy vaccine.
Under the partnership announced today, PROOF and Adiga will use patient samples from the trial for a biomarker discovery and validation program that has been established and refined by PROOF.
The partners aim to identify protein and genetic biomarkers that respond to vaccine treatment. Bruce McManus, director of the PROOF Centre, said in a statement that the biomarkers "will support the development of products for quicker relief from allergy symptoms as well as for more effective clinical management of those suffering from allergic rhinitis."
Financial and other terms of the deal were not disclosed.
PROOF, is a not-for-profit organization based in Vancouver, British Columbia that develops biomarker-based tests for patients with heart, lung, and kidney diseases. Based in Hamilton, Ontario, Adiga is a joint venture between McMaster University and UK-based biopharmaceutical firm Circassia and identifies and commercializes promising early-stage Canadian medical technologies.